Close Menu

NEW YORK (GenomeWeb) – Evercore ISI said today that it has initiated coverage of Twist Bioscience with an Outperform rating and a price target of $30.50.

In a note to investors, Evercore ISI Analyst Ross Muken and colleagues wrote that Twist can likely maintain a growth rate of more than 25 percent over the next three to five years through its DNA synthesis and NGS tools businesses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.